Tirzepatide delivered 20.9% weight loss versus semaglutide's 15.3%, but Medicare Part D still excludes anti-obesity drugs for 50 million beneficiaries.

Approximately 100 million US adults meet the diagnostic threshold for obesity, BMI 30 or above, and roughly 22 million have severe obesity, BMI 40 or above. Two GLP-1-based injectables dominate the treatment landscape: semaglutide 2.4mg (Wegovy, Novo Nordisk, approved June 2021) and tirzepatide (Zepbound, Eli Lilly, approved November 2023). Tirzepatide's SURMOUNT-1 trial demonstrated 20.9% weight loss against semaglutide's STEP 1 result of 15.3%, establishing a clear head-to-head efficacy advantage for the newer agent.

Medicare Part D has historically excluded anti-obesity medications, leaving roughly 50 million Medicare beneficiaries without prescription coverage. A proposed 2025 CMS rule to allow GLP-1 agents under Part D remains pending congressional action. Commercial payers require a BMI of 30 or above with at least one comorbidity, or a BMI of 35 or above alone, before granting prior authorization, creating substantial access barriers. Supply constraints for Wegovy persisted through 2023 and have partially eased by mid-2024.

Efficacy superiority means little while the largest payer, Medicare, still excludes the category.

Five questions this report answers:

Q1 - How are UHC, CVS/Aetna and Cigna differentiating prior authorization criteria between tirzepatide and semaglutide?

Q2 - What is the commercial impact of the proposed 2025 CMS rule allowing Medicare Part D GLP-1 coverage?

Q3 - Which pipeline oral agents, orforglipron and danuglipron, threaten injectable dominance in obesity by 2027?

Q4 - What BMI and comorbidity thresholds do commercial payers require before granting obesity drug prior authorization?

Q5 - How many of the roughly 100 million eligible US adults remain blocked by the Medicare Part D exclusion?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#Obesity #US #CompetitiveIntelligence #AXLRx #GLP1

Live report page:  https://axlrx.ai/obesity/competitive-intelligence/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-      hello@axlrx.ai

Web-      https://axlrx.ai/